Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating DNA, Circulating RNA, Circulating Tumor Cells

Martin Beaulieu's Biography

Martin Beaulieu, Director, Regulus Therapeutics Inc

Dr. Martin Beaulieu is a biochemist with expertise in the development of molecular applications and diagnostic assay development. In the past 16 years, Dr. Beaulieu has led research & development activities in academic and bio-pharmaceutical organizations. He holds a Bachelor of Science degree in Biochemistry (1993) from Laval University and a Ph.D. in Physiology-Endocrinology from the Faculty of Medicine (1998) at Laval University.
Dr. Beaulieu’s Ph.D. thesis focused on steroid hormones and drug metabolizing enzymes, called UGTs. His work contributed to the demonstration of the role of the UGT enzymes in controlling steroid hormones homeostasis and cellular hormonal response in cancer cells. He authored 20 peer-reviewed scientific publications. During a post-doctoral fellowship, Dr. Beaulieu developed a novel mutation detection assay at the Beckman Research Institute at the City of Hope National Medical Center in Duarte, CA. At Sequenom Inc., a genetic systems company in San Diego, he led the development and optimization of molecular applications based on MALDI-TOF Mass Spectrometry including the iPLEXTM genotyping product. At DiagnoCure Inc. Dr. Beaulieu led cancer biomarker discovery studies and the development of a high-value molecular diagnostic test for staging colorectal cancer (Previstage™). Recently, Dr. Beaulieu supported the management of diagnostic assay development at Abbott Point of Care and is currently leading the Regulus microMarkers™ R&D division at Regulus Therapeutics Inc.

Martin Beaulieu Image

Profiling MicroRNAs in Circulation

Tuesday, 24 March 2015 at 09:00

Add to Calendar ▼2015-03-24 09:00:002015-03-24 10:00:00Europe/LondonProfiling MicroRNAs in

Expression profiles of microRNAs are deregulated in cells undergoing pathophysiologic stress suggesting potential as markers of disease states.  MicroRNAs (miRs) are regulatory factors that function to repress the transcription of multiple mRNAs, thereby affecting several biological pathways.  Relative to other circulating nucleic acids, miRs are stable in circulation and are detectable in several biofluid types. To discover new markers to address clinical needs, we developed a highly reproducible quantitative miR profiling platform that is compatible with several sample types.   Under the Regulus MicroMarkers? division, Regulus has conducted large-scale profiling studies and has profiled over 3,000 clinical samples to date and has identified potential miR biomarkers for a variety of clinical conditions.  Recent results will be presented.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating DNA, Circulating RNA, Circulating Tumor